IBRX News & Events

Consensus $43.17M. ANKTIVA is now approved or authorized across five regulatory jurisdictions, representing approximately 34 countries. Additionally, the pivotal BCG-naive CIS trial is fully enrolled, with the IDMC confirming no additional enrollment is required. A supplemental BLA submission is on track for 2026. The Company ended the quarter with an estimated $380.9 million in cash, cash equivalents and marketable securities as of March 31, 2026. "ANKTIVA's continued momentum reflects growing physician adoption and disciplined commercial execution," said Richard Adcock, President and CEO of ImmunityBio. "Following strong growth in 2025, we are focused on scaling in the U.S. and expanding across an increasing number of global markets."

ImmunityBio announced it has submitted a comprehensive response to the U.S. Food and Drug Administration, FDA,Office of Prescription Drug Promotion, OPDP, regarding issues raised on March 13, 2026 related to a television advertisement and a podcast. The company addressed the concerns related to the podcast and informed OPDP that the television advertisement was never aired. ImmunityBio has taken proactive steps to address the OPDP's concerns, including the removal of the identified podcast from its corporate website and requesting its removal from third-party platforms. Additionally, the company confirmed that a television advertisement mentioned in the OPDP letter was never broadcast or disseminated to the public. "ImmunityBio takes promotional compliance with the utmost seriousness," said Richard Adcock, President and CEO of ImmunityBio. "We are dedicated to maintaining a clear distinction between our investigational pipeline aspirations and the promoted indications for our approved therapies. We believe our substantive remedial actions and enhanced internal protocols address the Agency's concerns."

ImmunityBio has secured $75M in non-dilutive financing under its existing Royalty Interest Purchase Agreement with Oberland Capital, increasing the total committed capital under the Agreement to $375M. The amended agreement maintains existing terms, with a modest increase in the royalty payback rate while maintaining the royalty cap. Simultaneous with the closing of the amendment to the RIPA, Nant Capital, an entity affiliated with our Executive Chairman, converted $25M principal amount with the issuance of 4.6M shares of the company's common stock to Nant Capital and the reduction of debt under the $505M December 2024 Promissory Note